FDA leadership transition will delay drug approvals

Market overview

With Makary departing, the FDA will face a leadership vacuum, slowing the approval process for new drugs. Historically, leadership changes at the FDA have correlated with temporary approval delays.

regulatory prediction market

Implied probability (Yes)

70%

Source: user-generated

More regulatory markets

• Crypto billionaire Harborne faces FCA scrutiny over £5m gift — 55% Yes
• Crypto billionaire Harborne will face FCA scrutiny — 60% Yes
• Crypto billionaire Christopher Harborne’s donation triggers FCA inquiry into funding transparency — 70% Yes
• Crypto billionaire Christopher Harborne will face parliamentary scrutiny over £5m gift — 55% Yes
• Harborne crypto holdings face regulatory scrutiny — 60% Yes
• SEC approves at least 2 new Bitcoin ETFs by Q4 2027 — 75% Yes
• SEC approves Kalshi's crypto futures products by 2026-Q3 — 55% Yes
• Iran's central bank bans crypto mining by 2027 Q1 — 85% Yes

Browse all regulatory markets →